Vitamin B3 Identified as Potential Lifesaving Treatment for Severe Genetic Disorder

A new study has identified vitamin B3 as a potential treatment for NAXD deficiency, a severe genetic disorder. This breakthrough offers hope for a condition that typically leads to mortality within the first few months of life.

NAXD deficiency is caused by genetic mutations that impair the function of the NAD(P)HX dehydratase enzyme (NAXD). This condition typically leads to mortality within the first first few months of life.

A Novel Approach to Discovering Vitamin Therapies

Researchers employed a non-traditional method, screening various vitamins for their ability to alleviate health problems. This innovative approach suggested that a wide range of health disorders could potentially respond to therapies involving vitamin B2 or B3.

Isha Jain, Ph.D., a Gladstone Institutes Investigator and senior study author, emphasized the objective behind this strategy.

"The objective is to systematically identify diseases treatable with specific vitamins using modern genetics, rather than relying on random supplementation."

Dramatic Results in Mouse Models

The findings were particularly striking in animal trials. In a mouse model of NAXD deficiency, vitamin B3 extended the lifespan by over 40 times and relieved disease symptoms. This remarkable outcome highlights the potential therapeutic power of the vitamin.

Redefining Vitamins as Therapeutic Agents

Vitamins are widely recognized as essential nutrients, with their deficiencies known to cause serious diseases. While vitamin supplement use is widespread, clear recommendations for their therapeutic application are often lacking. However, vitamins are inexpensive and accessible, offering potential as therapeutic agents.

The Jain lab initiated their research using CRISPR technology. They eliminated individual genes from human cell lines, then assessed if high levels of vitamins could improve the survival of these genetically altered cells. This screening technique revealed significantly improved survival for cells lacking NAXD when supplied with abundant vitamins.

From Lab Bench to Potential Clinical Impact

To confirm these initial cellular findings, researchers engineered a mouse model of NAXD deficiency. The results were compelling: NAXD-deficient animals treated with vitamin B3 immediately after birth remained healthy, normal, and lived for at least 300 days. In contrast, untreated NAXD-deficient mice died within days of birth. Further biomarker analysis confirmed that the biochemical pathway related to NAXD functioned normally in treated animals.

Early diagnosis will be critical for patients with NAXD deficiency. This groundbreaking research suggests that a simple and readily available therapy could be life-changing for affected individuals and their families.

"This research suggests that a simple and available therapy could be life-changing for affected individuals and their families."

Jain noted that these findings underscore the importance of incorporating NAXD deficiency into screening panels used to identify diseases in newborns.

A Scalable Framework for Future Discoveries

Jain further added that the method described in this study can be applied to discover other situations where vitamin therapy might alter the course of a disease and potentially prevent mortality.

"This framework is scalable and could identify vitamin therapies for hundreds of genetic diseases, with hopes for its application to other micronutrients."